BioCentury
ARTICLE | Regulation

Bypassing Germany

BI-Lilly, Novartis bypass Germany with 2 new drugs; blame AMNOG pricing reforms

September 19, 2011 7:00 AM UTC

The adoption of a comparative efficacy standard as part of Germany's new drug pricing reform law has made it even more difficult to obtain reimbursement above generics prices. As a result, some pharmas already have decided not to sell two new drugs in the country.

The new pricing scheme, known as AMNOG, allows a company to set its drug price at launch, at which time it must submit evidence of the drug's benefit over existing treatments to the German Federal Joint Committee (G-BA)...